ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

POLB Poolbeg Pharma Plc

7.35
0.21 (2.94%)
12 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Poolbeg Pharma Plc LSE:POLB London Ordinary Share GB00BKPG7Z60 ORD 0.02P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.21 2.94% 7.35 7.10 7.60 7.35 7.35 7.35 1,153,027 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 0 -3.93M -0.0079 -9.30 35.7M
Poolbeg Pharma Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker POLB. The last closing price for Poolbeg Pharma was 7.14p. Over the last year, Poolbeg Pharma shares have traded in a share price range of 7.05p to 15.70p.

Poolbeg Pharma currently has 500,000,000 shares in issue. The market capitalisation of Poolbeg Pharma is £35.70 million. Poolbeg Pharma has a price to earnings ratio (PE ratio) of -9.30.

Poolbeg Pharma Share Discussion Threads

Showing 3751 to 3774 of 3775 messages
Chat Pages: 151  150  149  148  147  146  145  144  143  142  141  140  Older
DateSubjectAuthorDiscuss
12/12/2024
14:36
"Jeremy has aged 10 years in the last 3 years."........ Maybe its hard work being so excited all the time.
owenski
12/12/2024
14:08
Is there a gossip of faked news ??
baldrick1
11/12/2024
07:15
I agree Chica, can't really be much fun trying to look enthusiastic all the time and he let's the guard down every now and then by making it look tired and forced. You would have thought one of their many pr consultants could have fixed them up with a bit of AI before releasing.
peterrr3
10/12/2024
22:35
Jeremy has aged 10 years in the last 3 years.
chica1
10/12/2024
20:30
I know you like this kind of thing Baldrick, a few happy snaps to show genuine crowds rushing poster 2061 and as a result keeping the share price north of 7p.https://www.linkedin.com/posts/poolbeg-pharma_ash24-polb-cancer-activity-7272143066654814208-2R0K?utm_source=share&utm_medium=member_ios
peterrr3
09/12/2024
14:54
Probably red today at 7p
baldrick1
09/12/2024
11:47
My friend is fibbing;)))
baldrick1
09/12/2024
09:08
I'll call a friend ;)))
baldrick1
09/12/2024
08:45
CF, well there's a reliable source if I ever saw one.
peterrr3
09/12/2024
08:33
Phone CF to confirm that it works and would not just potentially work as previously reported .Would anyone here make that call ?
baldrick1
09/12/2024
08:10
We've known this since November 6th..
chica1
09/12/2024
07:52
Thanks my apologies
peterrr3
09/12/2024
07:28
It’s a brand new trial.
troutisout
09/12/2024
07:25
Good morning,I hope all is well and please see link to RNS Reach issued by Poolbeg this morning: https://www.londonstockexchange.com/news-article/POLB/ poolbeg=presents-polb-001-data-at-66th-ash-meeting/16801054We are delighted to share key insights from our poster presented over the weekend at the prestigious 66th American Society of Hematology (ASH) annual meeting, the world's leading conference on hematological malignancies (blood cancers).The poster detailed data from the POLB 001 pre-clinical study which completed earlier this year. The study found that all doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome (CRS) scores and demonstrated superior cytokine inhibition compared to Adalimumab, an anti-TNF antibody which is a gold standard potent inhibitor of CRS in humanized tumour-bearing mouse models.The results of this animal study reinforce the use case forPOLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS. The previous successful LPS trial in healthy human volunteers also provides ratification.Addressing cancer immunotherapy-induced CRS holds the potential to greatly impact the treatment of hematological malignancies - enhancing safety and reaching more patients.We are delighted to have shared these significant insights with potential partners and experts in the field.Don't hesitate to contact me should you have any questions.Kind regards,Cathal Frielhttps://www.londonstockexchange.com/news-article/POLB/poolbeg-presents-polb-001-data-at-66th-ash-meeting/16801054
burtond1
09/12/2024
07:10
RNS presents years old trials results as news. Worth a go I guess.
peterrr3
06/12/2024
15:13
I'm not on telegram, and what do they know that's being kept secret from us ? ;))
baldrick1
06/12/2024
15:04
Or is this the telegram secret Santa?
peterrr3
06/12/2024
15:02
Seems to indicate you have joined them Baldy
peterrr3
06/12/2024
14:38
I do think CF and Co. Is giving the discreet nods up to the century buyers ;)))
baldrick1
06/12/2024
12:52
Let's hope we can join them ;))
baldrick1
06/12/2024
12:29
They are in a blackout for the Xmas party, so they can't.
peterrr3
06/12/2024
09:12
Are there anymore directors buying this?
baldrick1
28/11/2024
09:03
And I thought it was Xmas party season.One last roll of the dice before the festivities. Cheap Ryan Air flights, maybe you could go and report back Baldrick?https://www.linkedin.com/posts/poolbeg-pharma_polb-genecelltherapy-celltherapy-activity-7267807605450801152-RfZY?utm_source=share&utm_medium=member_ios
peterrr3
26/11/2024
13:47
I may take a punt when it drops to 4-5p before Xmas.
baldrick1
Chat Pages: 151  150  149  148  147  146  145  144  143  142  141  140  Older